MSD India Chief On The Now, Next For Januvia, Gardasil And Keytruda’s Ascent
MSD India managing director Rehan Khan talks to Scrip about price adjustments for Januvia and the brand’s strong physician recall amid a tsunami of competition post loss of exclusivity, as also plans for Gardasil, which faces upcoming competition from Indian vaccines star Serum Institute. He also signals huge strides made by Keytruda, now the top cancer therapy in the country.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: new data for Factor XIa inhibitors; Farxiga in heart failure; Lumakras succeeds in lung cancer; MSD’s India head on company plans; and BeiGene’s confidence in IO/IO combinations.
Glenmark signals “very challenging” US environment but expects things to stabilize with a string of potential new launches in the wings. The impending debut of Ryaltris, among other products, and a filing for a generic rival to Flovent could add some spark to the US business.
Keytruda- and Gardasil-driven revenue growth exceeded forecasts and Merck expects to keep the PD-1 blockbuster cash coming with earlier-stage indications and a potential subcutaneous formulation.